We are live on ! Find out more
RVMD icon

Revolution Medicines

90 hedge funds and large institutions have $1.98B invested in Revolution Medicines in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 39 increasing their positions, 11 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

422% more capital inflows, than outflows

Capital inflows: $330M | Capital outflows: $63.3M

255% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 11

108% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 12

29% more funds holding in top 10

Funds holding in top 10: 7 → 9 (+2)

17% more funds holding

Funds holding: 77 → 90 (+13)

6.35% more ownership

Funds ownership: 80.05% → 86.4% (+6.4%)

Holders
90
Holders Change
+13
Holders Change %
+16.88%
% of All Funds
1.81%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.18%
New
25
Increased
39
Reduced
11
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RVMD Hedge Fund Activity: Q3 2020 in Review

90 of the 4,973 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q3 2020, worth a combined $1.98B — up 33% from $1.49B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RVMD positions and 12 closed out — a net gain of 13 holders — while 39 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $59M. The largest seller was TRV GP III, cutting an estimated $27.7M.

  • 90 institutional investors held Revolution Medicines (RVMD) as of Q3 2020, up from 77 in Q2 2020.
  • Funds reported $1.98B of Revolution Medicines stock for Q3 2020, up 33% quarter-over-quarter.
  • 25 funds opened new Revolution Medicines positions in Q3 2020 and 12 closed out, a net change of +13 holders.
  • The largest Revolution Medicines buyer in Q3 2020 was Vanguard Group, an estimated $59M added.
  • The largest Revolution Medicines seller in Q3 2020 was TRV GP III, an estimated $27.7M sold.

Based on aggregated 13F filings for Q3 2020.